Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Ethical Drugs Market Up to \8,136.3 Bil. in FY2007: IMS Japan
July 7, 2008
- More Attendants, Questions at Major Pharmas' Shareholders' Meetings
July 7, 2008
- R&D NEWS IN BRIEF
July 7, 2008
- BUSINESS NEWS IN BRIEF
July 7, 2008
- 7-Year Strategy for Hepatitis Calls For Radical Cure Rate of 70% for Hepatitis C
July 7, 2008
- English-Speaking Japanese Executives Earn up to 30% More than Non-English Speaking Colleagues: Survey
July 7, 2008
- Generic Anticancer Drugs Used in 16% of Hospitals with 100 or More Beds: Survey
July 7, 2008
- Gov't to Maintain Policy to Cut \1.1 Tril.
July 7, 2008
- Abbott Vascular Applies for XIENCE V
June 30, 2008
- Abbott Japan to Increase Pharma Group Sales to US$1 Bil. within 2 Years
June 30, 2008
- Terumo Acquires Clinical Supply from Eisai
June 30, 2008
- SELF-MEDICATION NEWS IN BRIEF
June 30, 2008
- Taiyo Leads Industry by Production Capacity and Prices: Mr Aratani
June 30, 2008
- NEW PRODUCTS
June 30, 2008
- 29.4% of Prescriptions Substituted Resulting in Savings of \420 Mil. in May: Nihon Chouzai
June 30, 2008
- MTPC Aims at 20% Increase in Sales per MR to \156 Mil.
June 30, 2008
- Pharmacists Sometimes Interfere with Spread of Generics: Survey
June 30, 2008
- Asahi Kasei Expects Sales of Over \10 Bil. with Recomodulin
June 30, 2008
- Generics Delivery Service Still in Conceptual Phase: Yamato HD
June 30, 2008
- BUSINESS NEWS IN BRIEF
June 30, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…